Why the Bionomics share price crashed 37.5% lower today

The Bionomics Ltd (ASX:BNO) share price has crashed 37.5% lower today following the release of another disappointing study result…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the worst performers on the Australian share market on Wednesday has been the Bionomics Ltd (ASX: BNO) share price.

In morning trade the biopharmaceutical company's shares are down a massive 37.5% to a multi-year low of 3.5 cents.

This latest decline means that the Bionomics share price has now lost close to 94% of its value over the last 12 months.

Why is the Bionomics share price down 37% today?

Investors have been heading to the exits this morning after another disappointing study result for its BNC210 product candidate.

This morning the company announced the top line results of an exploratory trial of BNC210 for the treatment of agitation in elderly patients in a hospital setting.

According to the release, the results of the trial indicated that BNC210 treatment did not differentiate from placebo on the primary and secondary efficacy end points.

A comparison of the mean peak daily Pittsburgh Agitation Scale scores (observations of aberrant vocalisation, motor agitation, aggressiveness and resisting care) showed a gradual improvement for both BNC210 and placebo over the five-day treatment period, but without evidence of a treatment effect.

Professor Paul Rolan, Bionomics consultant chief medical officer, said: "Whilst the results of the trial do not support further development of BNC210 for treatment of agitation, given BNC210's consistent safety profile and the demonstration by pharmacometric exposure-response modelling of its potential to treat post-traumatic stress disorder, we remain confident in pursuing PTSD, provided that we can achieve the blood exposure levels predicted by the modelling analysis."

The company now intends to push ahead with a single ascending dose study in healthy volunteers to demonstrate that blood levels of BNC210 believed to be necessary to meet the primary endpoints for effectiveness in treating PTSD in any further trial are achievable using the new solid dose formulation.

The cost of this study is estimated to be $300,000 and results are anticipated to be available early in the fourth quarter of the calendar year.

After which, Dr Errol De Souza, Executive Chairman of Bionomics, revealed that Bionomics intends to proceed with the further formulation development and preparation for a second Phase 2 trial if "the proposed study with the solid dose formulation confirms that the required blood levels are achievable, and the FDA guidance supports a second Phase 2 trial of BNC210 in PTSD."

Elsewhere in the industry today, the CSL Limited (ASX: CSL) share price has pushed higher and the Mayne Pharma Group Ltd (ASX: MYX) share price is trading 1% lower at a multi-year low of 47.5 cents.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Coles, Liontown, Lovisa, and Wildcat shares are dropping today

These ASX shares are having a difficult session. But why?

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Materials Shares

Why are ASX lithium shares like Pilbara Minerals crashing on Tuesday?

Lithium stocks are getting another whack today.

Read more »

Miner and company person analysing results of a mining company.
Materials Shares

Up 2,150% in a year, why is the Wildcat Resources share price crashing today?

Investors appear displeased with Wildcat's latest update on the Tabba Tabba project.

Read more »

Happy couple enjoying ice cream in retirement.
Share Fallers

2 classic ASX 200 shares you can buy for cheap now to hold for years

Experts reckon these well-known stocks are in a temporary dip that shrewd investors could take advantage of.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Cettire, Fletcher Building, Lake Resources, and Nick Scali shares are falling today

These ASX shares are having a tough time on Monday. But why?

Read more »

Businessman puts hand over eyes on a sinking boat in ocean
Materials Shares

Down 80% in a year why are Lake Resources shares tumbling again today?

ASX lithium stock Lake Resources is under selling pressure again on Monday.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Ampol, Calix, Collins Foods, and Propel shares are tumbling today

These ASX shares are ending the week in the red. But why?

Read more »

A woman with short brown hair and wearing a yellow top looks at the camera with a puzzled and shocked look on her face as the Westpac share price goes down for no reason today
Share Fallers

Why Australian Finance Group, Chalice, DroneShield, and ResMed are sinking today

These ASX shares are having a tough time on Thursday. But why?

Read more »